Medicare Enrolled
Dr. Kimberly Harris, MD
Gastroenterology · Westlake, OH
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Harris from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harris?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Harris
Dr. Kimberly Harris is a gastroenterology specialist in Westlake, OH, with 17 years of NPI registration. Based on federal Medicare data, Dr. Harris performed 11,718 Medicare services across 624 unique beneficiaries.
Between the years covered by Open Payments, Dr. Harris received a total of $3,648 from 36 pharmaceutical and/or device companies across 194 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Harris is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 1% volume in OH
$3,648 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,718
Medicare services
Top 1% in OH for gastroenterology
624
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~689 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
10,806 | $17 | $40 |
| Tissue pathology examination, moderate complexity A laboratory test where a pathologist examines tissue samples under a microscope to analyze cellular details. This intermediate complexity procedure involves specialized techniques to identify abnormalities in the tissue. |
237 | $24 | $322 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
153 | $61 | $186 |
| Special stain test for organisms A laboratory test using special stains on tissue slides to identify microorganisms. The process includes the technical preparation of the slides and a professional interpretation of the results. |
84 | $62 | $405 |
| Special tissue stain and interpretation A laboratory test using special stains to examine tissue samples, including the pathologist's review and written report of the findings. |
77 | $50 | $235 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
58 | $193 | $950 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
55 | $78 | $756 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
54 | $44 | $174 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
48 | $90 | $266 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
38 | $78 | $231 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
36 | $82 | $980 |
| New patient office visit, 15-29 minutes An initial office visit for a new patient lasting 15 to 29 minutes. This code is used when the total time spent on the date of the encounter meets this duration threshold. |
18 | $35 | $148 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
16 | $151 | $650 |
| Balloon dilation of esophagus, stomach, or upper small bowel, less than 3.0 cm A procedure using a flexible endoscope to widen a narrowed section of the esophagus, stomach, or upper small bowel with a balloon that is less than 3.0 cm in length. |
13 | $95 | $1,991 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
13 | $64 | $174 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
12 | $74 | $650 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
92.7% high complexity
1.0% medium
6.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,648
Total received (2018-2024)
Avg $521/year across 7 years
Top 38% in OH for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
194
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,648 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,270
2023
$968
2022
$564
2021
$382
2020
$94
2019
$276
2018
$96
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$301
Takeda Pharmaceuticals U.S.A., Inc.
$216
ABBVIE INC.
$175
AIMMUNE THERAPEUTICS, INC.
$71
PFIZER INC.
$63
QOL Medical, LLC
$55
GENZYME CORPORATION
$49
Intercept Pharmaceuticals, Inc.
$45
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$38
Daiichi Sankyo Inc.
$35
Celltrion USA Inc.
$33
EVOKE PHARMA, INC.
$32
Lilly USA, LLC
$24
Merck Sharp & Dohme LLC
$21
Ardelyx, Inc.
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
Fresenius Kabi USA, LLC
$20
Braintree Laboratories, Inc.
$20
IRONWOOD PHARMACEUTICALS, INC
$17
Ipsen Biopharmaceuticals, Inc
$16
Top 3 companies account for 54.5% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$679
Janssen Biotech, Inc.
$424
Takeda Pharmaceuticals U.S.A., Inc.
$421
Janssen Scientific Affairs, LLC
$241
PFIZER INC.
$209
QOL Medical, LLC
$198
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$141
Merck Sharp & Dohme Corporation
$113
Organon LLC
$90
AIMMUNE THERAPEUTICS, INC.
$88
Daiichi Sankyo Inc.
$79
Celgene Corporation
$75
Merck Sharp & Dohme LLC
$74
Intercept Pharmaceuticals, Inc.
$73
AbbVie Inc.
$68
Nestle HealthCare Nutrition Inc.
$67
GENZYME CORPORATION
$49
Lilly USA, LLC
$49
RedHill Biopharma Inc.
$48
Ardelyx, Inc.
$45
Boehringer Ingelheim Pharmaceuticals, Inc.
$41
Fresenius Kabi USA, LLC
$38
AbbVie, Inc.
$38
Evoke Pharma, Inc.
$34
Celltrion USA Inc.
$33
EVOKE PHARMA, INC.
$32
Dynavax Technologies Corporation
$27
Gilead Sciences, Inc.
$26
Ferring Pharmaceuticals Inc.
$25
Regeneron Healthcare Solutions, Inc.
$24
Braintree Laboratories, Inc.
$20
NESTLE HEALTHCARE NUTRITION INC.
$17
IRONWOOD PHARMACEUTICALS, INC
$17
Ironwood Pharmaceuticals, Inc
$16
Ipsen Biopharmaceuticals, Inc
$16
Amgen Inc.
$15
Top 3 companies account for 41.8% of all-time payments
Associated products mentioned in payments ›
AMJEVITA · Aemcolo · Bylvay · CIMZIA · CREON · CYLTEZO · Creon · DIFICID · DUPIXENT · ENTYVIO · EOHILIA · Entyvio · GIMOTI · HUMIRA · Heplisav-B · Humira · IBSRELA · IDACIO · INJECTAFER · LINZESS · Linzess · MOTEGRITY · Motegrity · OCALIVA · OMVOH · REMICADE · RENFLEXIS · RINVOQ · SKYRIZI · STELARA · SUCRAID · SUTAB · Sucraid · TREMFYA · TRULANCE · Talicia · VEGZELMA · VELSIPITY · VIBERZI · VOWST · XELJANZ · XIFAXAN · ZENPEP · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Gastroenterologists within 10 mi
114
Per 100K population
9.1
County median income
$62,823
Nearest hospital
UH ST JOHN MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Harris is a mixed practice specialist, with above-average Medicare volume (top 1% in OH), with low-engagement industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Harris experienced with vedolizumab infusion (entyvio)?
Based on Medicare claims data, Dr. Harris performed 10,806 vedolizumab infusion (entyvio) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Harris receive payments from pharmaceutical companies?
Yes. Dr. Harris received a total of $3,648 from 36 companies across 194 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harris's costs compare to other gastroenterologists in Westlake?
Dr. Harris's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harris) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Westlake
Browse gastroenterologists in Westlake ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in OH
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in OH
Which OH gastroenterologists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology